Main Article Content
Introduction: The estimation, separation, and validation of Cabotegravir and Rilpivirine along with their
impurities were performed using the RP-HPLC technique. Materials and Methods: Cabotegravir, Rilpivirine,
and their respective impurities were separated on an Inertsil ODS column (150 × 4.6 mm, 3.5 μ) using a
mobile phase consisting of 5 mM Ammonium Formate and acetonitrile at a flow rate of 1 mL/min at room
temperature. The PDA detector from a Waters HPLC e-2695 quaternary pump was used with a wavelength of
231 nm. The linearity was investigated for 17 min with injection concentrations of 75–450 μg/mL of Rilpivirine,
50–300 μg/mL of Cabotegravir, and 1.25–7.5 μg/mL of each impurity of Cabotegravir and Rilpivirine. The validity
of the proposed method was verified using the International Conference on Harmonization (ICH) guidelines.
Results and Discussion: The results of method validation including specificity, linearity, accuracy, ruggedness,
and robustness were within the permissible range. Conclusion: The HPLC-MS technique successfully validated
the chemical structures of the degradation products of Cabotegravir and Rilpivirine, and stress studies were carried
out in compliance with ICH Q2 (R1) guidelines
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.